Skip header and navigation

3 records – page 1 of 1.

Patient Information for Cisapride

https://libcat.nshealth.ca/en/permalink/chpams37288
IWK. Gastroenterology, Nutrition & Paediatric Health Psychology Team, IWK. Pharmacy. Halifax, NS: IWK Health Centre , 2020.
Pamphlet Number
PL-1249
Available Online
View Pamphlet
Cisapride is a drug used to help the symptoms of certain types of problems, including acid reflux, slow stomach and severe constipation. Cisapride helps speed up stomach emptying and movement of food through the gut.
Available Online
View Pamphlet
Corporate Author
IWK. Gastroenterology, Nutrition & Paediatric Health Psychology Team
IWK. Pharmacy
Place of Publication
Halifax, NS
Publisher
IWK Health Centre
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document : digital, PDF file
Subjects (MeSH)
Cisapride
Gastrointestinal Agents
Gastrointestinal Diseases - drug therapy
Gastrointestinal Motility - drug effects
Pharmaceutical Preparations
Subjects (LCSH)
Gastrointestinal agents
Gastrointestinal system--Diseases--Chemotherapy
Gastrointestinal system--Motility--Disorders
Abstract
Cisapride is a drug used to help the symptoms of certain types of problems, including acid reflux, slow stomach and severe constipation. Cisapride helps speed up stomach emptying and movement of food through the gut.
Responsibility
IWK Gastroenterology, Nutrition & Paediatric Health Psychology Team, Halifax, NS
Pamphlet Number
PL-1249
Zone
All Zones
Less detail

Ustekinumab (Stelara) therapy for Crohn's disease

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. QEII. Gastroenterology. Halifax, NS: Nova Scotia Health Authority , 2017.
Pamphlet Number
1695
Available Online
View Pamphlet
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing thi…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Gastroenterology
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2017
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Crohn Disease - drug therapy
Subjects (LCSH)
Crohn's disease
Gastrointestinal agents
Abstract
Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn’s disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.
Responsibility
Prepared by: Alison Harding BSc, Jennifer Stewart RN, CCRP, Dr. Des Leddin; Gastroenterology
Pamphlet Number
1695
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Specialty
Medications
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1623
Less detail